Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Dana-farber-cancer Institute Inc.

The Broad Institute, Inc.

Bayer Schering Pharma Ag

Deutsches Krebsforschungszentrum

Bayer Animal Health Gmbh

Bayer Pharma Aktiengessellschaft

Bayer Pharma Aktiengesselschaft

Deutsches Krebsforschungszentrum Heidelberg

Ulf Bömer

Philip Lienau

Arne Scholz

Gerhard Siemeister

Dirk Kosemund

Knut Eis

Ludwig Zorn

Andrea Hägebarth

Ulrich Lücking

Rolf Bohlmann

Volker Schulze

Detlev Sülzle

Judith Günther

William Johnston Scott

Ulrich Bothe

Kirstin Petersen

Florian Puehler

Ningshu Liu

Hans Briem

Hartmut Rehwinkel

Benjamin Bader

Mark Jean Gnoth

Roland Neuhaus

Oliver Politz

Antje Margret Wengner

Ursula Mönning

Martin Lange

Stuart Ince

Holger Siebeneicher

Holger Steuber

Lars Bärfacker

Marcus Koppitz

Hartmut Schirok

Mario Lobell

Christian Stegmann

Reinhard Nubbemeyer

Duy Nguyen

Peter Hauff

Dirk Brohm

Alexandra Rausch

Reiner Fischer

Ulrich Klar

Klemens Lustig

Walter Hübsch

Kai Thede

Niels Lindner

Christoph-Stephan Hilger

Georg Kettschau

Lars Wortmann

Stefan Prechtl

Arne Von Bonin

Pierre Wasnaire

Wilhelm Bone

Tobias Marquardt

Clara Christ

Keith Graham

Julien Lefranc

Jens Schröder

Karl-Heinz Schlemmer

Dieter Lang

Adrian Tersteegen

Wahed Ahmed Moradi

Thomas Maier

Nils Griebenow

Bernd Buchmann

Anne Mengel

Nicholas Charles Ray

Markus Berger

Hans Schick

Thomas Beckers

Matthew Meyerson

Martina Schäfer

Karl-Heinz Thierauch

Norbert Schmees

Joerg Keldenich

Sven Ring

Andrea Rotgeri

Orlin Petrov

Ingo Hartung

Gang Chen

Joachim Telser

Simon Holton

Jens Hoffmann

Nicolas Werbeck

Iring Heisler

Marion Hitchcock

Jürgen Klar

Stefan Kaulfuss

Detlef Stöckigt

Stephan Siegel

Heidi Greulich

Matthias Vennemann

Kersten Matthias Gericke

Thomas Bär

Laura Furst

Georges Von Degenfeld

Tobias Heinrich

Gerd Ruhter

Detlev Suelzle

Dennis Kirchhoff

The present invention relates to compounds of formula (I) processes for their production and their use as pharmaceuticals. The compounds are inhibitors of Casein kinase 1 alpha and/or delta (CSNK1α and/or β) useful for the treatment of proliferative disorders.

3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said substituted indazoles, and use of said substituted indazoles to produce drugs

The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.

Substituted aminoquinolones as DGKalpha inhibitors for immune activation

Compounds of formula (I) processes for their production and their use as pharmaceuticals. 

4H-pyrrolo[3,2-c]pyridin-4-one derivatives

The present application relates to the use of fused heteroaromatic pyrrolidones for treatment and/or prophylaxis of allergic and/or inflammatory diseases in animals and to the use thereof for production of medicaments for treatment and/or prophylaxis of allergic and/or inflammatory diseases in animals, especially of atopic dermatitis and/or Flea Allergy Dermatitis, and especially in domestic animals, particularly in dogs.

Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals

The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R, R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients. 

Heteroarylbenzimidazole compounds

Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs

The present invention relates to 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients. 

5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines

2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs

The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I): in which A, E, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders

The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

Substituted pyridobenzodiazepinone-derivatives and use thereof

The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).

4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group

The present invention relates to novel macrocyclic compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I). 

Macrocyclic compounds

Growing community of inventors

Glienicke, Germany

Ulf Bömer